Collij, Lyduine E;
Bollack, Ariane;
La Joie, Renaud;
Shekari, Mahnaz;
Bullich, Santiago;
Roé-Vellvé, Núria;
Koglin, Norman;
... AMYPAD consortium; + view all
(2024)
Centiloid recommendations for clinical context-of-use from the AMYPAD consortium.
Alzheimers Dementia
10.1002/alz.14336.
(In press).
Preview |
Text
Barkhof_Alzheimer s Dementia - 2024 - Collij - Centiloid recommendations for clinical context‐of‐use from the AMYPAD consortium.pdf Download (1MB) | Preview |
Abstract
Amyloid-PET quantification through the tracer-independent Centiloid (CL) scale has emerged as an essential tool for the accurate measurement of amyloid-β (Aβ) pathology in Alzheimer's disease (AD) patients. The AMYPAD consortium set out to integrate existing literature and recent work from the consortium to provide clinical context-of-use recommendations for the CL scale. Compared to histopathology, visual reads, and cerebrospinal fluid, CL quantification accurately reflects the amount of AD pathology. With high certainty, a CL value below 10 excludes the presence of Aβ pathology, while a value above 30 corresponds well with pathological amounts. Values falling in between these two cutoffs ("intermediate range") are related to an increased risk of disease progression. Together, CL quantification is a valuable adjunct to visual assessments of amyloid-PET images. An abnormal amyloid biomarker assessment is a key criterion to determine eligibility for anti-amyloid disease-modifying therapies, and amyloid-PET quantification can add further value by precisely monitoring amyloid clearance, and hence guiding patient management decisions. HIGHLIGHTS: Centiloid (CL) quantification robustly reflects of the amount of Aβ pathology. CL < 10/CL > 30 reflects Aβ-negativity/positivity thresholds with high certainty. CL quantification is a valuable adjunct to visual assessments of amyloid-PET. CL quantification can support trial design and treatment management. CL quantification could support the identification of early or emerging Aβ pathology.
Type: | Article |
---|---|
Title: | Centiloid recommendations for clinical context-of-use from the AMYPAD consortium |
Location: | United States |
Open access status: | An open access version is available from UCL Discovery |
DOI: | 10.1002/alz.14336 |
Publisher version: | http://dx.doi.org/10.1002/alz.14336 |
Language: | English |
Additional information: | This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, providedthe original work is properly cited.© 2024 The Author(s). Alzheimer’s & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer’s Association. |
Keywords: | Amyloid‐β, Centiloid quantification, clinical trials, positron emission tomography |
UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > UCL BEAMS UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Brain Repair and Rehabilitation UCL > Provost and Vice Provost Offices > UCL BEAMS > Faculty of Engineering Science > Dept of Med Phys and Biomedical Eng |
URI: | https://discovery.ucl.ac.uk/id/eprint/10200719 |
1. | China | 2 |
2. | United Kingdom | 1 |
3. | United States | 1 |
Archive Staff Only
View Item |